Results 61 to 70 of about 960 (168)

Multidimensional fragmentomic profiling of cell-free DNA released from patient-derived organoids

Human Genomics, 2023
Background Fragmentomics, the investigation of fragmentation patterns of cell-free DNA (cfDNA), has emerged as a promising strategy for the early detection of multiple cancers in the field of liquid biopsy.
Jaeryuk Kim, Seung-Pyo Hong, Seyoon Lee, Woochan Lee, Dakyung Lee, Rokhyun Kim, Young Jun Park, Sungji Moon, Kyunghyuk Park, Bukyoung Cha, Jong-Il Kim   +10 more
doaj   +1 more source

From Tumour to Bloodstream: Advancing PD‐L1 Testing With Liquid Biopsies in Non‐Small Cell Lung Cancer

Cytopathology, EarlyView.
This review explores liquid biopsy as a complementary approach to tissue‐based PD‐L1 assessment in advanced NSCLC treated with immune checkpoint inhibitors. Focusing on circulating tumour cells, extracellular vesicles, and circulating tumour DNA, it summarises current evidence, technical challenges, and future perspectives for personalised ...
R. Leporati, V. Callegari, A. Ancora, M. Palmieri, B. Riccò, E. Cabitza, L. Trudu, K. Di Emidio, C. Chiavelli, A. Eccher, I. Mastrolia, V. Catani, S. Bettelli, G. Guaitoli, M. Dominici, F. Bertolini   +15 more
wiley   +1 more source

Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection

Molecular Cancer, 2022
Early detection can benefit cancer patients with more effective treatments and better prognosis, but existing early screening tests are limited, especially for multi-cancer detection.
Hua Bao, Zheng Wang, Xiaoji Ma, Wei Guo, Xiangyu Zhang, Wanxiangfu Tang, Xin Chen, Xinyu Wang, Yikuan Chen, Shaobo Mo, Naixin Liang, Qianli Ma, Shuyu Wu, Xiuxiu Xu, Shuang Chang, Yulin Wei, Xian Zhang, Hairong Bao, Rui Liu, Shanshan Yang, Ya Jiang, Xue Wu, Yaqi Li, Long Zhang, Fengwei Tan, Qi Xue, Fangqi Liu, Sanjun Cai, Shugeng Gao, Junjie Peng, Jian Zhou, Yang Shao   +31 more
doaj   +1 more source

Blood‐Based Circulating Tumor DNA Assays for Early Colorectal Cancer Detection: A Systematic Review of Performance in Asymptomatic Screening Populations

International Journal of Cancer, Volume 159, Issue 4, Page 1028-1041, 15 August 2026.
Early detection of colorectal cancer via population‐based screening programs can reduce incidence and mortality, but current screening approaches are limited. This systematic review evaluated the screening potential of blood‐based circulating tumor DNA assays in asymptomatic screening populations.
Caroline Ledertoug Kahn, Maria Wissing Rasmussen, Jakob Kleif, Inge Søkilde Pedersen, Christina Therkildsen   +4 more
wiley   +1 more source

Access to diagnosis using liquid biopsy (ADLiB): Identifying lymphoma in a tuberculosis‐endemic setting

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract In HIV‐ and tuberculosis (TB)‐endemic regions, lymphoma diagnosis is often delayed because symptoms can overlap with TB, and access to biopsy and specialized pathology is limited. To address this, we developed and internally evaluated the Access to Diagnosis using Liquid Biopsy (ADLiB) platform—a plasma cell‐free DNA (cfDNA)‐based approach ...
Katherine Antel, Nina Xiong, Mwanasha Merrill, Taiyang Chen, Lauren McGrath, Clara Droessler, Maxine van der Schyff, Meng‐Xuan Wu, Dylan Cheddie, Charlotte Slome, Liam McBride, Jonathan Day, Zainab Mohamed, Nazia Fakie, Nomonde Mbatani, Charlotte Shultz, Graeme Meintjes, Svitlana Tyekucheva, Elizabeth F. Cohen, Michael Y. Tolstorukov, Estelle Verburgh, Mark A. Murakami   +21 more
wiley   +1 more source

Post‐surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection

International Journal of Cancer, Volume 158, Issue 10, Page 2771-2783, 15 May 2026.
What's New? Circulating nuclear DNA (cir‐nDNA)‐based assessment of minimal residual disease (MRD) offers powerful post‐surgery prognostic insight for stage III colon cancer (CC). Sparse knowledge of post‐surgical variations and origins in cir‐nDNA, however, has limited its clinical application.
Andrei Kudriavtsev, Saidi Daoud, Catalina Isabel Cofre Muñoz, Alexia Mirandola, Ekaterina Pisareva, Javier Gonzalo Ruiz, Marco Macagno, Nadia Saoudi Gonzalez, Evelyne Crapez, Marc Ychou, Ramon Salazar Soler, Elisabetta Fenocchio, Paula X. Fernandez Calotti, Thibault Mazard, Cristina Santos Vivas, Elena Elez, Federica Di Nicolantonio, Alain R. Thierry   +17 more
wiley   +1 more source

Histone Modifications in Cardiovascular Disease: Mechanisms and Therapeutic Opportunities

MedComm, Volume 7, Issue 5, May 2026.
This graphical abstract summarizes how classical and emerging histone posttranslational modifications (PTMs), together with their chromatin regulators (writers, erasers, and readers), govern major pathobiological programs in cardiovascular disease.
Yu Zheng, Yu‐Xuan Gao, Mei‐Xing Guo, Li‐Ting Wang, Xiao‐Wen Zheng, Yi‐Hao Liao, Ya Li, Jun‐Ping Zhu, Jia‐Ming Wei   +8 more
wiley   +1 more source

Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025

Cancer Innovation, Volume 5, Issue 2, April 2026.
This review summarizes key breakthrough advances in hepatocellular carcinoma (HCC) reported in 2025 and presents a multidisciplinary management framework for HCC, integrating early diagnosis, microenvironment insights, and comprehensive therapeutic strategies spanning minimally invasive surgery, locoregional interventions, and systemic pharmacotherapy.
Bo Hu, Qiang Gao
wiley   +1 more source

Tracing the Origin of Cell-Free DNA Molecules through Tissue-Specific Epigenetic Signatures

Diagnostics, 2022
All cell and tissue types constantly release DNA fragments into human body fluids by various mechanisms including programmed cell death, accidental cell degradation and active extrusion.
Angela Oberhofer, Abel J. Bronkhorst, Carsten Uhlig, Vida Ungerer, Stefan Holdenrieder   +4 more
doaj   +1 more source

Whole‐genome sequencing of cell‐free DNA for assessment of minimal residual disease in high‐risk smoldering multiple myeloma

HemaSphere, Volume 10, Issue 4, April 2026.
Abstract In multiple myeloma (MM), minimal residual disease (MRD) is an established endpoint for accelerated drug approval but is limited by a need for serial invasive bone marrow (BM) biopsies, which may under‐sample spatial heterogeneity and result in false negativity.
Chrissy Baker, Elizabeth Hill, Dickran Kazandjian, Marios Papadimitriou, Michael Durante, Abhishek Pandey, Bachisio Ziccheddu, Tomas Jelinek, David Coffey, Brian Walker, Ryan Young, Kylee Maclachlan, Neha Korde, Nickoli Parkinson, Zoe R. Goldstein, Alexi Runnels, William F. Hooper, Dan Landau, Nicolas Robine, Francesco Maura, Ola Landgren, Benjamin Diamond   +21 more
wiley   +1 more source